|
Name | Last | Chg |
---|---|---|
Dow Jones | 38239.66 | 0.40% |
NASDAQ | 15927.90 | 2.03% |
|
Name | Last | Chg |
---|---|---|
Dow Jones | 38239.66 | 0.40% |
NASDAQ | 15927.90 | 2.03% |
Symbol | Last | Chg |
---|---|---|
IBRX | 7.3500 | 43.84% |
AGEN | 11.6900 | 40.84% |
ULH | 45.8400 | 39.37% |
KPLT | 12.7600 | 35.74% |
MOBX | 3.5000 | 33.59% |
Symbol | Last | Chg |
---|---|---|
MFI | 2.3300 | 77.68% |
NWGL | 5.0450 | 70.06% |
ATXI | 6.2000 | 29.34% |
BACK | 3.9200 | 23.14% |
PROK | 2.1200 | 21.77% |
Symbol | Last | Chg |
---|---|---|
PEGY | 0.0626 | 20.62% |
SQQQ | 11.4300 | 4.75% |
INTC | 31.8800 | 9.20% |
TSLA | 168.2900 | 1.11% |
SOFI | 7.8700 | 3.69% |
(Adds details in paragraphs 4-7, background throughout)
March 28 (Reuters) - The U.S. Centers for Disease
Control and Prevention issued an advisory on Thursday alerting
healthcare providers about an increase in invasive meningococcal
disease and urging them to ensure necessary vaccinations against
the deadly disease.
Meningococcal disease, caused by the bacterium Neisseria
meningitidis, is a serious bacterial infection that commonly
affects the brain, spinal cord and bloodstream.
As of Monday, 143 cases had been reported, compared with 81
cases this time last year, the CDC said. There were 422 cases
recorded last year, the highest annual number since 2014.
The increase in infections is mainly attributable to a
particular bacterial strain in the meningococcal bacteria group
Y.
An infection with this strain had disproportionately
affected people aged 30–60 years, African American people, and
people with HIV, the agency said, urging healthcare providers to
have a "heightened suspicion" for meningococcal disease among
these populations.
The agency also warned that patients may present with
bloodstream or joint infection and without symptoms typical of
meningitis, which include fever, headache, and stiff neck.
Four of the six meningococcal bacteria groups - A, B, C, W,
X, and Y - circulate in the United States, according to the CDC,
with vaccines available against all except the X group.
In October, the U.S. Food and Drug Administration approved
Pfizer's
against five meningococcal bacteria groups.
Pfizer currently sells two vaccines to protect against
the disease, with Trumenba targeting the B group and Nimenrix
protecting against the other four bacteria groups.
(Reporting by Mariam Sunny in Bengaluru; Editing by Devika
Syamnath and Alan Barona)
((Mariam.ESunny@thomsonreuters.com;))